Fails 1 of 8 criteria. S5, analytical documentation: No certificate, lot number or test result is reachable. A product page prints a Batch Tested badge with nothing behind it, the only certificate-of-analysis language on the site is editorial prose setting that test for other sellers, and none of the 107 asset references across 240 pages is a certificate.
Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.
A telehealth service selling compounded semaglutide and tirzepatide beside four brand GLP-1 drugs at cash-pay rates, with NAD+ and sermorelin. Its own footer states that some content on the site is generated by artificial intelligence, on all 240 pages read.
What was read, where, and on what date, for each disposition in the table above.
S1PASSA clinician licensed in the buyer's own state reviews the intake before any prescription is issued, and eight jurisdictions are named where a live video visit comes first. Two physicians are named with National Provider Identifier numbers.Source: pallashealth.co/clinical.
S2PASSEligibility questions gate the order, and checkout is shown as the last of four stages. The walk ran eleven screens from a weight-loss goal to a contraindication list naming pancreatitis and medullary thyroid carcinoma without reaching it. The terms disclose a refundable deposit of up to 60 dollars taken at checkout, before a clinical decision.Source: pallashealth.co/get-started/weight-loss/diabeticStatus.
S3PASSSix filling pharmacies are named with telephone numbers and web addresses: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills Pharmacy. No street address is printed for any of the six, and state license numbers are offered on request rather than published.Source: pallashealth.co/clinical.
S4PASSA footer statement on every page reads that compounded medications are not approved by the Food and Drug Administration and are not generic versions of brand-name drugs. A clinical page repeats it and names the four brands the compounded product is not equivalent to.Source: pallashealth.co/clinical.
S5FAILNo certificate, lot number or test result is reachable. A product page prints a Batch Tested badge with nothing behind it, the only certificate-of-analysis language on the site is editorial prose setting that test for other sellers, and none of the 107 asset references across 240 pages is a certificate.Source: pallashealth.co/treatments/glp-1.
S6PASSEvery page prints 131 Continental Drive, Suite 305, Newark, Delaware in its footer, beside a telephone number and an email address. It is the only postal address on the site, and no pharmacy or clinical premises address appears.Source: pallashealth.co/terms.
S7PASSPrices are printed on public pages before intake. Compounded semaglutide runs 139 dollars for a first month and then 597 dollars every twelve weeks, compounded tirzepatide 179 dollars for a first month and then 897 dollars every twelve weeks, and the four brand drugs are billed monthly from 1,069 to 1,349 dollars for a 28-day supply.Source: pallashealth.co/treatments/glp-1.
S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, compounded sermorelin, Wegovy, Ozempic, Zepbound, Mounjaro, NAD+ injection, NAD+ nasal spray.
Unpaid link. Pallas Health does not pay the site, and nothing is earned when it is used. Funding.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.